Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SHP099 hydrochloride 是一种有效的、选择性的、口服生物可利用的、有效的 SHP2 抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 278 | 现货 | ||
5 mg | ¥ 655 | 现货 | ||
10 mg | ¥ 982 | 现货 | ||
25 mg | ¥ 1,650 | 现货 | ||
50 mg | ¥ 2,390 | 现货 | ||
100 mg | ¥ 3,590 | 现货 | ||
500 mg | ¥ 8,120 | 现货 | ||
1 g | ¥ 9,820 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 659 | 现货 |
产品描述 | SHP099 is a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor. |
靶点活性 | SHP2:70 nM. |
体外活性 | The X-ray co-crystal for SHP099 with SHP2 reveals a new interaction with the basic amine and the Phe113 backbone carbonyl. SHP099 exhibits inhibition of cell proliferation (KYSE-520 model) with an IC50 of 1.4 μM. SHP099 also exhibits high solubility and high permeability with no apparent efflux in Caco-2 cells[1]. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, therefore, inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signaling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells[2]. |
体内活性 | Dose-dependent exposure and modulation of the pharmacodynamic marker p-ERK was observed in xenografts following single doses of 30 and 100 mg/kg (red and blue lines, respectively). A daily oral dose of 10 or 30 mg/kg yield 19% and 61% tumor growth inhibition, respectively. Tumor stasis is achieved at 100 mg/kg[1]. |
激酶实验 | The inhibition of SHP2 from the tested compounds (SHP099) concentrations varying from 0.003-100 μM is monitored using an assay in which 0.5 nM of SHP2 is incubated with of 0.5 μM of peptide IRS1_pY1172(dPEG8)pY1222. After 30-60 minutes incubation at the surrogate substrate, DiFMUP is added to the reaction and incubated at 25 °C for 30 minutes. The reaction is then quenched by the addition of 5 μL of a 160 μM solution of bpV(Phen). The fluorescence signal is monitored using a microplate reader using excitation and emission wavelengths of 340 nm and 450 nm, respectively[1]. |
细胞实验 | Cells are plated onto 96-well plates in 100 μL medium. SHP099 with various concentrations (1.25, 2.5, 5, 10, 20 μM) are added 24 h after cell plating. At day 5, 50 μL Celltiter-Glo reagent is added, and the luminescent signal is determined[1]. |
分子量 | 388.72 |
分子式 | C16H20Cl3N5 |
CAS No. | 2200214-93-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Methanol: 15 mg/mL (38.59 mM), Sonication is recommended.
DMSO: 55 mg/mL (141.49 mM), Sonication and heating are recommended.
H2O: 10 mg/mL (25.73 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Methanol / DMSO / H2O | 1 mM | 2.5725 mL | 12.8627 mL | 25.7255 mL | 64.3136 mL |
5 mM | 0.5145 mL | 2.5725 mL | 5.1451 mL | 12.8627 mL | |
10 mM | 0.2573 mL | 1.2863 mL | 2.5725 mL | 6.4314 mL | |
20 mM | 0.1286 mL | 0.6431 mL | 1.2863 mL | 3.2157 mL | |
DMSO | 50 mM | 0.0515 mL | 0.2573 mL | 0.5145 mL | 1.2863 mL |
100 mM | 0.0257 mL | 0.1286 mL | 0.2573 mL | 0.6431 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SHP099 hydrochloride 2200214-93-1 Metabolism Others Phosphatase SHP-099 SHP099 Hydrochloride SHP 099 Inhibitor SHP 099 Hydrochloride inhibit SHP-099 Hydrochloride SHP-099 hydrochloride SHP099 inhibitor